Results 131 to 140 of about 12,515 (211)

The Mechanisms of Resistance to Tyrosine Kinase Inhibitor Imatinib Therapy of Chronic Myeloid Leukemia

Медицинский вестник Юга России, 2010
Imatinib mesylate is a potent and high selective inhibitor of Bcr-Abl tyrosine kinase, which is established now as the standard of Philadelphia chromosome positive (Ph) chronic myeloid leukemia (CML) treatment.
S. I. Kutsev, S. V. Mordanov, A. N. Zeltser, O. S. Oxenjuk, O. A. Ustaeva, T. I. Kungurova, E. V. Burnasheva, E. Grankina, Yu. V. Shatokhin   +8 more
doaj  

Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls [PDF]

, 2004
Hagop M. Kantarjian, Susan O’Brien, Jorge E. Cortés, Francis J. Giles, Jianqin Shan, Mary Beth Rios, Stefan Faderl, Srđan Verstovšek, Guillermo Garcia‐Manero, William G. Wierda, Steven M. Kornblau, Alessandra Ferrajoli, Michael J. Keating, Moshe Talpaz   +13 more
openalex   +1 more source

Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance

Revista Brasileira de Hematologia e Hemoterapia, 2013
OBJECTIVE: The goal of this study was to monitor imatinib mesylate therapeutically in the Tumor Biology Laboratory, Department of Hematology and Hemotherapy, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (USP).
Vinícius Marcondes Rezende, Ariane Julio Rivellis, Melissa Medrano Gomes, Felipe Augusto Dörr, Mafalda Megumi Yoshinaga Novaes, Luciana Nardinelli, Ariel Lais de Lima Costa, Dalton de Alencar Fisher Chamone, Israel Bendit   +8 more
doaj  

Current results on the use of imatinib mesylate in patients with relapsed philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation

, 2003
Andrew J. Ullmann, Georg Heß, Karin Kolbe, Anne Friedrich-Freksa, Ralf G. Meyer, Harald Gschaidmeier, Christoph Huber, Thomas Fischer   +7 more
openalex   +2 more sources

Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia [PDF]

, 2004
Carlos E. Bueso‐Ramos, Jorge E. Cortés, Moshe Talpaz, Susan O’Brien, Francis J. Giles, Mary Beth Rios, L. Jeffrey Medeiros, Hagop Kantarjian   +7 more
openalex   +1 more source

Nail lichen planus associated with imatinib mesylate. [PDF]

JAAD Case Rep
Axler E, Loesch E, Vaidya T, Neubauer Z, Lipner SR.   +4 more
europepmc   +1 more source

Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate. [PDF]

Front Oncol, 2022
Siti Mariam I, Norhidayah R, Zulaikha AB, Nazihah MY, Rosline H, Kausar GA, Sarina S, Azlan H, Ankathil R.   +8 more
europepmc   +1 more source

Indications for Imatinib Mesylate Therapy and Clinical Management [PDF]

, 2004
François Guilhot
openalex   +1 more source

Compatibility Studies of Different Crystal Forms of Imatinib Mesylate with Pharmaceutical Excipients. [PDF]

ACS Omega
Mou Y, Zhao Y, Wen S, Li X, Zhang W, Xu X, Wang Y.   +6 more
europepmc   +1 more source

Periorbital Oedema and epiphora as ocular side effects of imatinib Mesylate (Gleevec) [PDF]

, 2004
Bita Esmaeli, Roxana Diba, Moloud Ahmadi, H.G. Saadati, Misha Faustina, Todd R. Shepler, Moshe Talpaz, R. W. Fraunfelder, Mary Beth Rios, Hagop M. Kantarjian   +9 more
openalex   +1 more source